Last reviewed · How we verify
Vaxneuvance vaccine — Competitive Intelligence Brief
phase 3
Immunology
Biologic
Live · refreshed every 30 min
Target snapshot
Vaxneuvance vaccine (Vaxneuvance vaccine) — Sanofi. Vaxneuvance vaccine works by stimulating the body's immune system to produce a protective response against COVID-19.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Vaxneuvance vaccine TARGET | Vaxneuvance vaccine | Sanofi | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Vaxneuvance vaccine CI watch — RSS
- Vaxneuvance vaccine CI watch — Atom
- Vaxneuvance vaccine CI watch — JSON
- Vaxneuvance vaccine alone — RSS
Cite this brief
Drug Landscape (2026). Vaxneuvance vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/vaxneuvance-vaccine. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab